A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment

In this pilot randomized clinical trial, IGNITE-TX was feasible to deliver in a community-recruited cohort with structural barriers to care and was associated with higher CGT completion and improved informed decision-making and readiness compared with non–IGNITE-TX arms. These findings support further evaluation of IGNITE-TX as a scalable navigation model for equitable hereditary cancer care.

Corresponding Author: J. Alejandro Rauh-Hain, MD, MPH, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030-1362 (jarauh@mdanderson.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.